There were empty seats in San Francisco last week at an annual international science conference which has delivered some of the world's most groundbreaking HIV research. It was a throwback to another ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

The Trump administration's decision to pause U.S. foreign aid has "substantially disrupted" supply of HIV treatments in eight ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

T'puram: A group of four unidentified assailants vandalized a medical shop in Neyyattinkara after the shopkeeper refused to sell them sleeping pills without a doctor's prescription. The incident ...

Biktarvy maintained HIV-1 suppression in 95.4% and HBV suppression in 86.6% of participants after 96 weeks of treatment switch. Lenacapavir with teropavimab and zinlirvimab showed 96% virologic ...

96% of patients on VH109 IV and 88% on VH109 SC kept HIV-1 RNA below 50 copies/mL at six months. VH184’s highest dose led to a maximum viral load drop of -2.69 log10 without resistance mutations.

Russian President Vladimir Putin said Thursday he supported the general idea of a U.S.-backed ceasefire with Ukraine, but he listed a number of conditions that would need to be met. "We agree with ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) following the success of a Phase I study.